Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression of miRNAs in patient-derived cancer models and models of drug resistance

ABSTRACT: Expression of miRNAs in patient-derived cancer models and models of drug resistance

PROVIDER: PRJNA877846 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21484282.fastq.gz	Fastqsanger.gz
	SRR21484283.fastq.gz	Fastqsanger.gz
	SRR21484284.fastq.gz	Fastqsanger.gz
	SRR21484285.fastq.gz	Fastqsanger.gz
	SRR21484286.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Tumor evolution and drug response in patient-derived organoid models of bladder cancer

Project description:Tumor evolution and drug response in patient-derived organoid models of bladder cancer

| PRJNA407895 | ENA

Patient-derived models of prostate cancer

Project description:Patient-derived models of prostate cancer

| PRJNA1000652 | ENA

Patient-derived models of prostate cancer

Project description:Patient-derived models of prostate cancer

| PRJNA1000653 | ENA

Expression of miRNAs in patient-derived cancer models and models of drug resistance

Project description:We examined whether tumor samples can be stratified according to miRNA expression profiles.

2023-11-01 | GSE212897 | GEO

Tumor evolution and drug response in patient-derived organoid models of bladder cancer

Project description:Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied and relatively lacking in suitable models. Here we describe a biobank of patient-derived organoid lines that recapitulates the spectrum of human bladder cancer at the histopathological and molecular levels. Organoid lines can be established efficiently from patient biopsies, including from patients before and after disease recurrence, and are interconvertible with orthotopic xenografts. Notably, these organoid lines often retain tumor heterogeneity and exhibit changes in their mutational profiles that are consistent with tumor evolution in culture. Analyses of drug response using bladder tumor organoids show partial correlations with mutational profiles as well as changes associated with treatment resistance, and specific responses can be validated using xenografts in vivo. Overall, our studies indicate that patient-derived bladder tumor organoids represent a model system for studying tumor evolution and treatment response in the context of precision cancer medicine.

2018-04-09 | GSE103990 | GEO

Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance

Project description:Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance

| PRJNA534119 | ENA

Species-specific quantitative proteomics profiles of sarcoma patient-derived models closely reflect their primary tumors　

Project description:Availability of patient-derived sarcoma models that closely mimic human tumors remains a significant gap in cancer research as these models may not recapitulate the spectrum of sarcoma heterogeneity seen in patients. To characterize patient-derived models for functional studies, we made proteomic comparisons with originating sarcomas representative of the three intrinsic subtypes by mass spectrometry. Human protein profiling was found to be retained with high fidelity in patient-derived models. Patient derived xenografts locally invade and colonize stroma in mice which enables unambiguous molecular discrimination of human proteins in the tumor from mouse proteins in the microenvironment. We characterized protein profiling of patient sarcoma tumors and mouse stroma by species-specific quantitative proteomics. We found that protein expression in mouse stroma was affected by the primary human tumor. Our results showed that levels of stromal proteins derived from the tumor were lowered in PDXs and cell lines and part of human stromal proteins were replaced by corresponding mouse proteins in PDXs. This suggests that the effects of the microenvironment on drug response may not reflect those in the primary tumor. This cross-species proteomic analysis in PDXs could potentially improve preclinical evaluation of treatment modalities and enhance the ability to predict clinical trial responses.

2020-03-22 | PXD013185 | JPOST Repository

chromatin Remodeling in Patient-Derived Colorectal Cancer Models

Project description:chromatin Remodeling in Patient-Derived Colorectal Cancer Models

| PRJNA764740 | ENA

Construction of GBM patient-derived xenograft mouse models

Project description:Construction of GBM patient-derived xenograft mouse models

| PRJNA857591 | ENA

Construction of GBM patient-derived xenograft mouse models

Project description:Our adult GBM patient-derived xenograft mouse models keep the genomics characteristics of GBM patient tumors.

2023-07-12 | GSE207886 | GEO